Introduction
============

Breast cancer is one of the most common malignancies among females ([@b1-or-35-06-3178]), which can occur in humans and other mammals, and most cases are women ([@b2-or-35-06-3178]). Over 1 million persons are diagnosed with breast cancer each year ([@b3-or-35-06-3178]). Similarly to other cancers, carcinogenesis of breast cancer is a complex process. Although mortality rate of breast cancer has been observably reduced, metastatic breast cancer still remains puzzling ([@b4-or-35-06-3178]). The mechanisms of carcinogenesis and metastasis need to be better clarified.

MicroRNA (miRNA) is a class endogenous non-coding single-stranded RNA. As circulating marker, miRNA is being studied extensively ([@b5-or-35-06-3178],[@b6-or-35-06-3178]). miRNAs are able to downregulate approximately 1/3 human genes by binding to 3′-untranslated region (3′-UTR) of target mRNA ([@b5-or-35-06-3178],[@b7-or-35-06-3178]). miRNAs are involved in many biological processes, such as cell proliferation, apoptosis, migration and carcinogenesis ([@b8-or-35-06-3178]--[@b11-or-35-06-3178]). Many miRNAs are also involved in carcinogenesis and development of breast cancer ([@b9-or-35-06-3178],[@b10-or-35-06-3178]). It has been shown that miR-200c, miR-206, miR-335, miR-494 and miR-125b are downregulated in breast cancer tissues, suggesting that they may play tumor suppressor roles ([@b12-or-35-06-3178]--[@b16-or-35-06-3178]). As oncogenes of breast cancer, miR-155, miR-21, miR-210, miR-373 and miR-10b are upregulated in patients with breast cancer ([@b17-or-35-06-3178]--[@b20-or-35-06-3178]). The miR-214 is decreased in breast cancer ([@b21-or-35-06-3178]), and miR-218 is also known as a tumor suppressor in prostate cancer, hepatocellular carcinoma and glioblastoma ([@b22-or-35-06-3178]--[@b24-or-35-06-3178]), but the mechanisms of both miR-214 and miR-218 are unclear.

In the present study, we investigate the expression of miR-214 and miR-218 in breast cancer and adjacent tissues, and analyzed the correlations in miR-214 and miR-218 expression and the clinicopathological characteristics. The effects of miR-214 or miR-218 on cell proliferation, apoptosis and cell cycle were also determined *in vitro*. Our results may provide new biomarkers for diagnosis, prognosis and therapy, and be helpful to clarify the mechanisms of post-transcription regulation in breast cancer.

Materials and methods
=====================

Clinical samples
----------------

Forty-nine breast cancer tissues and their paired adjacent tissue samples, which were diagnosed by pathological surgical resection, were collected between 2013 and 2015 at The First Hospital of Hebei Medical University (Shijiazhuang, China). The tissues were frozen in liquid nitrogen at −80°C immediately until use. Breast cancer patients who had undergone chemotherapy or radiation therapy before surgery were excluded.

Ethics statements
-----------------

Permission to use human tissue samples for research purposes was approved by the Biomedical Ethics Committee of Hebei Medical University, Shijiazhuang, Hebei, China. All patients were female and consented to participate in the present study.

Cell line and transfection
--------------------------

Breast cancer cell line MCF-7 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA), cultured in RPMI-1640 containing 10% fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 mg/ml of streptomycin (Gibco, Grand Island, NY, USA) in a humidified atmosphere containing 5% CO~2~ at 37°C. For transfection, cells were seeded and cultured for 24 h in 12-well plates. According to the manufacturer\'s instructions, cells were transfected with miR-214 mimic, miR-218 mimic or negative control, respectively, by Lipofectamine 2000 (Invitrogen Life Technologies, Grand Island, NY, USA) in serum-free medium. Six hours after the transfection, the complete medium was changed and maintained for 48 h at 37°C in 5% CO~2~. The mimics of miR-214, miR-218 and negative control were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China).

Real-time reverse transcription polymerase chain reaction (real-time RT-PCR)
----------------------------------------------------------------------------

Total RNA was extracted from breast cancer tissues, adjacent tissues and MCF-7 cells by TRIzol reagent (Invitrogen), according to the manufacturer\'s instructions. Reverse transcription PCR and real-time PCR were performed with TaqMan microRNA Reverse Transcription kit and TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA, USA, respectively) following standard protocol. U6 was used as an endogenous control to normalize variance. The primers of miR-214, miR-218 and U6 were purchased from Applied Biosystems. The fold changes were calculated via relative quantification (2^−ΔCT^).

Cell proliferation assay
------------------------

Cell proliferation was determined by the Cell Counting kit-8 assay (CCK-8; Dojindo Molecular Technologies, Inc., Beijing, China). MCF-7 cells (1,000 cells/well) were cultured in 96-well plates. After incubation, 10 *µ*l of the CCK-8 solution was added to each well of the plate, and incubated for 1 h in the incubator, and the absorbance was measured at 450 nm using a microplate reader according to the CCK-8 kit manufacturer\'s instructions.

Flow cytometry
--------------

The effects of miR-214 and miR-218 on breast cancer cell apoptosis and cell cycle were examined by flow cytometry (BD Biosciences, Mansfield, MA, USA). In brief, MCF-7 cells were transfected with miR-214 mimic, miR-218 mimic or negative control for 48 h, the cells were completely collected including apoptotic cells in culture medium, and washed twice with cold PBS. The cell apoptosis were analyzed by Annexin V-FITC detection kit (Neobioscience Technology, Shenzhen, China) according to the manufacturer\'s protocol. For determining the cell cycle, the cells were transfected for 48 h, washed twice with PBS, treated with trypsin, and fixed with 75% ethanol overnight at −20°C, and incubated with 100 mg/ml RNase A and 50 mg/ml propidium iodide (PI) at room temperature for 30 min. The percentage of the G0/G1, S and G2/M populations were evaluated in each group. The data were analyzed by CellQuest Pro software. Each experiment was performed in triplicate.

Wound-healing assay
-------------------

MCF-7 cells were grown to confluence. A wound was made by scraping with a conventional pipette tip across the confluence cell layer, and washed with PBS twice. Forty-eight hours after scraping, migration was determined, using the ImageJ, as a percentage of healing area relative to the initial wound area.

Statistical analysis
--------------------

Data were processed by the SPSS Graduate Pack 13.0, GraphPad 5 software or the Student\'s t-test. P\<0.05 was considered to be statistically significant.

Results
=======

miR-214 and miR-218 are downregulated in breast cancer tissues
--------------------------------------------------------------

To assess the effects of miR-214 and miR-218 on breast cancer development, we first evaluated miR-214 and miR-218 expression levels in breast cancer and adjacent cancer tissues by real-time RT-PCR. The expression of miR-214 and miR-218 was significantly downregulated in breast cancer tissues compared with matching adjacent tissues (P\<0.01, respectively; [Fig. 1](#f1-or-35-06-3178){ref-type="fig"}).

Correlation of miR-214 or miR-218 expression with clinicopathological data
--------------------------------------------------------------------------

We further evaluated the correlation of miR-214 or miR-218 expression and the clinicopathological factors, including age, tumor size, lymph node metastasis, clinical stage, estrogen receptor (ER), progesterone receptor (PR), epidermal factor receptor-2 (HER-2), p53 and Ki-67. ER, PR, HER-2, p53 and Ki-67 were detected by immunohistochemistry, respectively. When the number of stained cells was \>10% in one field, it was defined as positive. We found that miR-214 and miR-218 expression was negatively associated with Ki-67 expression ([Fig. 2A and C](#f2-or-35-06-3178){ref-type="fig"}; P=0.025, 0.018, respectively), and the expression of PR was positively associated with miR-218 ([Fig. 2D](#f2-or-35-06-3178){ref-type="fig"}; P=0.027), but not miR-214 ([Fig. 2B](#f2-or-35-06-3178){ref-type="fig"}; P=0.4). There was no correlation between the miR-214 or miR-218 expression level with age, tumor size, lymph node metastasis, stage, ER, HER-2 and p53 ([Table I](#tI-or-35-06-3178){ref-type="table"}).

Overexpression of miR-214 and miR-218 inhibits the breast cancer cell proliferation
-----------------------------------------------------------------------------------

To test the biological function of miR-214 and miR-218, the miR-214 mimic, miR-218 mimic and negative controls were purchase from Applied Biosystems. The overexpression of miR-214 or miR-218 was carried out in MCF-7 cells by transfection with miR-214 mimic or miR-218 mimic, respectively. The expression of miR-214 ([Fig. 3A](#f3-or-35-06-3178){ref-type="fig"}) and miR-218 ([Fig. 3B](#f3-or-35-06-3178){ref-type="fig"}) were detected by real-time RT PCR in transfected cells. To investigate the effect of miR-214 and miR-218 on cell proliferation, cell proliferation assay were performed by the Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies), according to the manufacturer\'s instructions. After transfection with miR-214 and miR-218 mimic, respectively, the cells proliferation was significantly reduced compared to negative control transfected MCF-7 cells ([Fig. 3C](#f3-or-35-06-3178){ref-type="fig"}). The data showed that miR-214 and miR-218 were able to regulate cell proliferation of breast cancer.

Overexpression of miR-214 and miR-218 perturbs breast cancer cell cycle
-----------------------------------------------------------------------

The cell cycles were analyzed by flow cytometry (BD Biosciences) after staining with propidium iodide (PI). The percentage of cells in the G0/G1, S and G2/M phases was, respectively, evaluated under the negative control ([Fig. 4A](#f4-or-35-06-3178){ref-type="fig"}), miR-214 ([Fig. 4B](#f4-or-35-06-3178){ref-type="fig"}) or miR-218 ([Fig. 4C](#f4-or-35-06-3178){ref-type="fig"}) mimic transfection. As shown in [Fig. 4D](#f4-or-35-06-3178){ref-type="fig"}, the percentage of S phase cells was significantly decreased in miR-214 overexpressed MCF-7 cells comparing with control cells (13.21±1.38 vs. 17.20±0.39, P=0.0298), accompanied by an increase of G0/G1 phase cell ratio (79.78±2.29 vs. 76.08±0.02, P=0.11, no-statistical significance). The percentage of G0/G1 phase cells was significantly reduced in miR-218 overexpressed MCF-7 cells compared with control cells (65.74±1.40 vs. 76.08±0.02, P=0.006; [Fig. 4D](#f4-or-35-06-3178){ref-type="fig"}), and a marked increase of the cell ratio of S phase was observed in the miR-218 mimic transfected cells, compared to control cells (27.62±0.98 vs. 17.20±0.39, P=0.0009; [Fig. 4D](#f4-or-35-06-3178){ref-type="fig"}). The results confirmed that miR-214 and miR-218 disturbed the breast cancer cell cycle.

Overexpression of miR-214 and miR-218 induced early breast cancer cells apoptosis
---------------------------------------------------------------------------------

The cells were seeded into 6-well plates and transfected with negative control, miR-214 or miR-218 mimic, and cell apoptosis were analyzed by Annexin V-FITC detection kit according to the manufacturer\'s protocol. Representative results of negative control ([Fig. 5A](#f5-or-35-06-3178){ref-type="fig"}), miR-214 mimic ([Fig. 5B](#f5-or-35-06-3178){ref-type="fig"}), and miR-218 mimic ([Fig. 5C](#f5-or-35-06-3178){ref-type="fig"}) are shown, respectively. The ratio of early apoptosis was analyzed by flow cytometry ([Fig. 5D](#f5-or-35-06-3178){ref-type="fig"}). The results confirmed that cell apoptosis was significantly augmented in the miR-214 or miR-218 mimic transfected cells. These results verified that miR-214 and miR-218 were able to mediate breast cancer cell apoptosis.

Overexpression of miR-214 and miR-218 reduced breast cancer cell migration
--------------------------------------------------------------------------

Cell migration was tested by wound-healing assay. Cell migration was decreased in miR-214 mimic (28.02±0.89 vs. 44.38±3.71%, P=0.013) and miR-218 (27.07±5.75 vs. 44.38±3.71%, P=0.017) mimic treated cells compared with negative control transfected cells ([Fig. 6A and B](#f6-or-35-06-3178){ref-type="fig"}). These results demonstrated that overexpression of miR-214 or miR-218 could inhibit breast cancer cell migration.

Discussion
==========

The expression of miR-214 has been verified downregulated in human cervical cancer ([@b25-or-35-06-3178]--[@b27-or-35-06-3178]), pancreatic cancer ([@b28-or-35-06-3178]), hepatocellular carcinoma ([@b29-or-35-06-3178],[@b30-or-35-06-3178]) and breast cancer ([@b28-or-35-06-3178]) and miR-218 expression is also reduced in oral squamous cell carcinoma, nasopharyngeal carcinoma, and bladder cancer cells ([@b31-or-35-06-3178]--[@b34-or-35-06-3178]). However, the molecular biological functions of miR-214 and miR-218 have not clarified in breast cancer. In the present study, we comprehensively evaluated the biological functions of miR-214 and miR-218 in breast cancer. The results indicated that miR-214 and miR-218 function as tumor suppressor genes in breast cancer.

In particular, expression of miR-214 and miR-218 was reduced in human breast cancer tissues, and miR-214 or miR-218 expression is negatively associated with Ki-67, a cellular marker of tumor cells proliferation ([Fig. 2](#f2-or-35-06-3178){ref-type="fig"}). *In vitro*, we also validated that miR-214 and miR-218 negatively mediated MCF-7 cell proliferation and interfered with cell cycle ([Figs. 3](#f3-or-35-06-3178){ref-type="fig"} and [4](#f4-or-35-06-3178){ref-type="fig"}). Previous studies have already demonstrated that the miR-214 could suppress oncogenesis of bladder cancer by targeting the p53 and DNA damage-regulated protein 1 (PDRG1) ([@b35-or-35-06-3178]), inhibit the progression of hepatocellular carcinoma by regulating β-catenin ([@b36-or-35-06-3178],[@b37-or-35-06-3178]), also mediating cell proliferation by targeting ERK ([@b38-or-35-06-3178]), mitochondrial transcription factor A (TFAM) ([@b39-or-35-06-3178]) and ADP-ribosylation factor-like protein 2 (ARL2) ([@b40-or-35-06-3178]). The miR-218 suppresses lung cancer and cardiac myxoma cell growth by reducing myocyte enhancer factor 2D (MEF2D) ([@b41-or-35-06-3178],[@b42-or-35-06-3178]), inhibits glioma cells proliferation by inactivation of cyclin D1 ([@b43-or-35-06-3178]) pathway and directly target E2F2 ([@b24-or-35-06-3178]), reduces bladder cancer and esophageal squamous cells proliferation by targeting BMI-1 ([@b34-or-35-06-3178],[@b44-or-35-06-3178]). The above evidence supports our conclusion.

Our results also prove that the miR-214 and miR-218 promote early apoptosis of breast cancer cells ([Fig. 5](#f5-or-35-06-3178){ref-type="fig"}). The effects of miR-214 are inconsistent, but some studies above confirm that overexpression of miR-214 can promote apoptosis and the sensitivity of cisplatin ([@b45-or-35-06-3178],[@b46-or-35-06-3178]). In addition, miR-218 promoted prostate cancer cells apoptosis by repression tumor protein D52 ([@b22-or-35-06-3178]), enhanced chemotherapy sensitivity by targeting BIRC5 and breast cancer 1 ([@b47-or-35-06-3178],[@b48-or-35-06-3178]), sensitized glioma cells to apoptosis by regulating NF-κB ([@b49-or-35-06-3178]). Our results, and the previous results imply that miR-214 and miR-218 could protect against tumorigenesis by inducing apoptosis.

The effects of miR-214 and miR-218 on breast cancer cell migration are shown in [Fig. 6](#f6-or-35-06-3178){ref-type="fig"}. Some previous research supports our results, there is evidence to prove that miR-214 could directly bind to the 3′-UTR of vascular endothelial growth factor (VEGF) ([@b50-or-35-06-3178]), the 3′-UTR of polypeptide GalNAc transferase 7 ([@b26-or-35-06-3178]) and the 3′-UTR of PTEN ([@b51-or-35-06-3178]). The miR-218 also suppresses the cancer cell migration or invasion by downregulating high mobility group box 1, LIM and SH3 protein 1, T-cell lymphoma invasion and metastasis 1 (TIAM1), matrix metalloproteinase 2 and 9 ([@b52-or-35-06-3178]--[@b54-or-35-06-3178]). These genes induced cell migration or invasion. Other targets of miR-214 and miR-218 will be analyzed in the following study. Interestingly, the expression of miR-214 and miR-218 are positively associated with PR ([@b55-or-35-06-3178]), although there is no statistic difference between miR-214 and PR expression. Many investigators consider that PR promotes cell migration, but some investigators still assert that progesterone or PR could exert cell migration inhibitory action ([@b56-or-35-06-3178]--[@b59-or-35-06-3178]). Our results suggest that PR may, via mediating miR-214 or miR-218, inhibit breast cancer migration.

In conclusion, our results show that miR-214 and miR-218 expression are decreased in breast cancer tissues. Overexpression of miR-214 or miR-218 could suppress cell proliferation and migration, disturb the cell cycle and induce cell apoptosis *in vitro*. Our findings suggest that miR-214 and miR-218, as tumor suppressors, could play important roles in development of breast cancer, and may be potential therapeutic targets for breast cancer. Therefore, further research on miR-214 and miR-218 functional mechanisms in breast cancer is required.

The present study was supported by the Science and Technology Support Project of Hebei, China (no. 14277755D).

![The expression of miR-214 and miR-218 were decreased in breast cancer tissues. The (A) expression of miR-214 and (B) miR-218 was detected in breast cancer tissues and adjacent tissues of 49 patients by real-time RT PCR. The P-values were assessed by non-parametric test.](OR-35-06-3178-g00){#f1-or-35-06-3178}

![Correlation analysis of miR-214 and miR-218, respectively, and clinicopathological data. The correlation between (A and B) miR-214 or (C and D) miR-218 expression and Ki-67 or progesterone receptor (PR) were evaluated, respectively. Ki-67 and PR were detected by immunohistochemistry, when the number of stained cells was \>10% in one field, it was defined as positive. The P-values were assessed by non-parametric test. NS, indicates no statistical difference.](OR-35-06-3178-g01){#f2-or-35-06-3178}

![Overexpression of miR-214 and miR-218 inhibits breast cancer cell proliferation. (A) expression of miR-214 and (B) miR-218 was upregulated with the transfection of miR-214 mimic or miR-218 mimic in MCF-7 cells, respectively. (C) Forty-eight hours after transfection, the cell proliferation was determined by CCK-8 assay. The experiments were performed in triplicate. ^\#^P=0.0253 (miR-214 mimic transfected cells vs. negative control cells). ^\*^P=0.0282 (miR-218 mimic transfected cells vs. negative control cells).](OR-35-06-3178-g02){#f3-or-35-06-3178}

![Effects of miR-214 and miR-218 on the cell cycle of breast cancer. After transfection, the cells were washed with PBS twice, and treated with trypsin. The surviving cells were collected, excepting apoptotic cells, in culture medium. The cell cycles were analyzed by flow cytometry after staining with PI. The representative results of cell cycles are shown in (A) negative control, (B) miR-214 mimic and (C) miR-218 mimic transfected cells. (D) In addition, the percentage of cells in the G0/G1, S and G2/M phases was, respectively, evaluated. The experiments were performed in triplicate. ^\*^P=0.0298 (the percentage of S phase cells, miR-214 mimic transfected cells vs. negative control cells). ^&^P=0.0009 (the percentage of S phase cells, miR-218 mimic transfected cells vs. negative control cells). ^\#^P=0.006 (the percentage of G0/G1 phase cells, miR-218 mimic transfected cells vs. negative control cells).](OR-35-06-3178-g03){#f4-or-35-06-3178}

![Effects of miR-214 and miR-218 on apoptosis of breast cancer cells. After (A) negative control, (B) miR-214 mimic and (C) miR-218 mimic transfection, the cells were collected including apoptotic cells in culture medium. In addition, cell apoptosis was analyzed by Annexin V-FITC detection kit. (A--C) Representative results are shown. (D) The percentage of early apoptotic cells was calculated, respectively. The experiments were performed in triplicate. The P-values were assessed by the Student\'s t-test.](OR-35-06-3178-g04){#f5-or-35-06-3178}

![Effects of miR-214 and miR-218 on migration capability of breast cancer cells. After negative control, miR-214 mimic and miR-218 mimic transfection, the cell migration was measured by wound-healing assay. (A) Representative results are shown. (B) The percentage of healing area was determined using the ImageJ. The experiments were performed in triplicate. The P-values were assessed by the Student\'s t-test.](OR-35-06-3178-g05){#f6-or-35-06-3178}

###### 

Correlations of miR-214 and miR-218 expression and the clinicopathological characteristics of breast cancer patients.

  Parameters                                                    No. of patients   Relative miR-214 expression Median (interquartile range)   P-value   Relative miR-218 expression Median (interquartile range)   P-value
  ------------------------------------------------------------- ----------------- ---------------------------------------------------------- --------- ---------------------------------------------------------- ---------
  Age (years)                                                                                                                                0.27                                                                 0.81
   ≤52                                                          25                104.02 (26.96--689.51)                                               43.73 (10.42--179.10)                                      
   \>52                                                         24                116.64 (26.30--221.89)                                               47.39 (13.84--144.50)                                      
  Tumor size (cm)                                                                                                                            0.82                                                                 0.63
   ≤2                                                           17                122.86 (25.15--427.12)                                               30.29 (5.10--248.76)                                       
   \>2                                                          32                107.23 (29.92--246.91)                                               47.38 (18.90--100.79)                                      
  Lymph node metastasis                                                                                                                      0.90                                                                 0.94
   Negative                                                     23                110.43 (26.69--406.72)                                               50.74 (15.88--94.53)                                       
   Positive                                                     26                94.33 (26.87--294.63)                                                43.88 (12.79--170.83)                                      
  Clinical stage[a](#tfn1-or-35-06-3178){ref-type="table-fn"}                                                                                0.77                                                                 0.72
   I                                                            11                124.65 (23.62--447.52)                                               81.16 (7.47--303.16)                                       
   II, III                                                      38                107.23 (27.63--253.54)                                               43.88 (15.25--119.50)                                      
  ER                                                                                                                                         0.77                                                                 0.32
   Negative                                                     13                122.86 (37.19--160.50)                                               26.69 (10.39--160.97)                                      
   Positive                                                     36                90.27 (26.04--437.32)                                                57.13 (18.77--161.17)                                      
  Her-2                                                                                                                                      0.82                                                                 0.68
   Negative                                                     20                65.41 (17.21--698.63)                                                35.18 (9.21--161.17)                                       
   Positive                                                     29                123.76 (38.05--255.90)                                               50.74 (16.05--163.83)                                      
  p53                                                                                                                                        0.29                                                                 0.16
   Negative                                                     33                65.81 (22.50--333.40)                                                40.06 (9.82--132.00)                                       
   Positive                                                     16                124.21 (48.80--398.44)                                               58.11 (24.42--329.89)                                      

No stage IV patients. ER, estrogen receptor; PR, progesterone receptor; HER-2, epidermal growth factor receptor-2.
